The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | Results of the COG AALL0434 trial for T-cell malignancies
Patients with T-cell leukemias typically have a worse prognosis than those with B-cell malignancies. In this interview, Kimberly Dunsmore, MD, from Virginia Tech Carilion School of Medicine, Roanoke, VA, discusses the results of the COG AALL0434 trial (NCT00408005), which is the largest T-cell malignancy trial to date. The aims of this trial were to investigate whether it is safe to administer nelarabine to patients with T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia, and whether treating these patients with high-dose or escalating-dose methotrexate is more effective when they are given as part of complex chemotherapy protocols. Prof. Dunsmore lastly speaks to the next steps for this study. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
